Covaxin for kids: Bharat Biotech's partner requests approval for ages 2-18 in US

Bharat Biotech's US partner Ocugen has approached US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18

New Delhi: Ocugen, Bharat Biotech's US partner, has announced that it had asked the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18. "We are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners - Ocugen," tweeted Dr Raches Ella, Bharat Biotech's clinical lead for Covid-19 vaccines.

There was a tweet posted from Ocugen's social media handle as well.